Hallucinogens is a broad pharmacological and common-language term for psychoactive substances that produce hallucinations — perceptions in the absence of external stimuli — and other profound alterations of consciousness, including distorted sensory experiences, ego dissolution, mystical states, and altered time perception. The term encompasses several pharmacologically distinct subclasses that produce similar phenomenological outcomes through very different mechanisms.
The major subclasses are: (1) classical psychedelics (serotonergic hallucinogens), including LSD, psilocybin, DMT, and mescaline, which act primarily as 5-HT2A receptor agonists; (2)dissociatives, including ketamine, PCP, DXM, and nitrous oxide, which produce altered consciousness through NMDA receptor antagonism; (3)deliriants, including tropane alkaloid-containing plants (datura, belladonna), diphenhydramine, and benzydamine, which produce true hallucinations through anticholinergic or other mechanisms; and (4)miscellaneous hallucinogens that do not fit neatly into these categories, including Salvia divinorum (kappa-opioid agonist) and Amanita muscaria (GABA-A modulator/NMDA agonist).
"Hallucinogen" is increasingly disfavored as a primary technical term in pharmacological literature in favor of more mechanistically precise classifications (serotonergic psychedelic, dissociative anesthetic) or culturally contextual terminology (entheogen). The broader term remains useful as a category that captures the common phenomenological thread across these mechanistically diverse compounds — that of profoundly altered states of consciousness involving non-ordinary perceptions — while acknowledging that the experiences differ substantially in character, utility, and risk across subclasses.
Safety at a Glance
High Risk- Know Your Subclass
- Reagent testing is especially important in this class because adulteration or misidentification is common:
- Toxicity: Class-Specific Risk Profiles No single toxicity profile applies to all hallucinogens. Risk varies enormously between ...
- Overdose risk: Limited specific overdose data is available for Hallucinogens. In the absence of compound-specifi...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Duration
No duration data available.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(4)
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Cognitive & Perceptual Effects
Visual(1)
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Cognitive(5)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
Transpersonal(1)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
Pharmacology
Mechanistically Diverse Category
Hallucinogens produce similar observable outcomes through radically different pharmacological mechanisms. Understanding these distinctions is essential for interpreting the safety, effects, and therapeutic potential of specific compounds.
Classical Psychedelics — 5-HT2A Agonism
Psilocin, LSD, DMT, mescaline, and related compounds are partial or full agonists at serotonin 5-HT2A receptors concentrated in layer V pyramidal neurons of the prefrontal cortex and cortical associative areas. Receptor activation disrupts predictive coding — the brain's normal hierarchical processing of sensory information — increasing "entropy" in cortical networks and allowing a broader, less filtered stream of experience to reach consciousness. Default Mode Network suppression correlates with ego dissolution. The result is intensified sensory perception, geometric hallucinations, unusual cognitive associations, emotional amplification, and in higher doses, profound changes in self-experience.
Dissociatives — NMDA Antagonism
Ketamine, PCP, DXM, MXE, and nitrous oxide block NMDA glutamate receptors, disrupting corticolimbic integration of sensory and self-referential processing. The resulting dissociative state — a disconnection between awareness, perception, and embodied sensation — is qualitatively different from serotonergic psychedelia: more detached, more introspective-to-the-point-of-withdrawal, and at high doses producing the "K-hole" or "DXM plateau IV" state of complete sensory dissociation.
Deliriants — Anticholinergic and Other Mechanisms
True anticholinergic deliriants (atropine, scopolamine, hyoscyamine from datura/belladonna; diphenhydramine at high doses) block muscarinic acetylcholine receptors in the CNS, producing genuine hallucinations — fully-formed waking dream experiences that users often cannot distinguish from reality — along with the anticholinergic toxidrome (tachycardia, dry mouth, urinary retention, hyperthermia). This experience is typically described as terrifying and meaningless rather than illuminating.
Miscellaneous
Salvia divinorum produces intense, short-lived (5–10 minute) hallucinogenic states through selective kappa-opioid receptor agonism. Ibogaine produces a long, visionary experience through complex multi-receptor pharmacology including sigma-1 and kappa-opioid agonism.
Interactions
No documented interactions.
History
Historical Overview
Human use of hallucinogenic plants predates written history. Mescaline-containing cacti have been found in archaeological sites in the Southwestern United States and Mexico dating to 5,700 years ago. Psilocybin mushrooms appear in rock art from Sub-Saharan Africa and Mesoamerica. Ayahuasca use by Amazonian peoples has been documented for at least 1,000 years. The Eleusinian Mysteries of ancient Greece may have employed ergot-derived compounds for 2,000 years.
Ethnobotanical Discovery
Western scientific awareness of hallucinogens expanded rapidly in the mid-20th century through the work of ethnobotanists and chemists. R. Gordon Wasson's 1957 Life magazine article documenting his participation in a Mazatec mushroom ceremony reached millions of readers and ignited Western interest in psychedelics. Albert Hofmann synthesized psilocybin and psilocin from Psilocybe mexicana in 1958–1959. Mescaline had been isolated from peyote cactus in 1897 by Arthur Heffter. LSD's discovery in 1943, also by Hofmann, became the defining moment of modern psychedelic history.
Psychedelic Research Era and Prohibition
The 1950s and 1960s saw intense academic and clinical research interest in hallucinogens — hundreds of studies examining their therapeutic potential and mechanisms of consciousness. This research era was terminated by the political and cultural response to psychedelic counterculture: LSD and psilocybin were placed on Schedule I in the United States in 1970 under the Controlled Substances Act. Global treaty obligations through the UN Convention on Psychotropic Substances (1971) spread scheduling worldwide.
Research Renaissance
Beginning in the late 1990s and accelerating through the 2000s–2020s, a new generation of researchers — at Johns Hopkins, Imperial College London, NYU, and other institutions — has systematically studied psilocybin, LSD, DMT, and MDMA. Results have been consistently promising for depression, PTSD, addiction, and existential distress. Multiple jurisdictions have moved toward decriminalization or legalized therapeutic frameworks.
Harm Reduction
Know Your Subclass
The harm reduction guidance that applies to LSD does not apply to datura. The most important first step in hallucinogen harm reduction is correctly identifying what you have and understanding which subclass it belongs to — as the risks, appropriate doses, and emergency management differ substantially.
Reagent testing is especially important in this class because adulteration or misidentification is common:
- Ehrlich reagent (purple with indoles — psilocybin, LSD, DMT): Confirms presence of an indole compound
- Hofmann reagent: More specific for LSD vs other indoles
- If Ehrlich is negative for something sold as psilocybin or LSD: Do not use — NBOMe compounds, DOx compounds, and PCP analogs have all been found in misrepresented samples
Absolutely Avoid Datura and Tropane Alkaloid Plants
Datura, Brugmansia (angel's trumpet), henbane, and mandrake are the single most dangerous category within the hallucinogens. Potency is highly variable even within a single plant; the margin between an "experience" and a fatal overdose is narrow; the experience is reliably described as terrifying rather than illuminating; and anticholinergic toxicity (cardiac arrhythmia, hyperthermia, rhabdomyolysis) is life-threatening. Harm reduction for these substances is: do not use.
Set and Setting Apply Most Strongly to Classical Psychedelics
For serotonergic psychedelics (LSD, psilocybin, mescaline, DMT), the principles of set and setting — mental state, physical environment, interpersonal context — are the most powerful determinants of experience quality. Invest time in preparation.
Safe Tripping with Dissociatives
For ketamine and similar compounds: never use near water, always have a sober companion, and protect your bladder with infrequent use and low doses.
Toxicity & Safety
Class-Specific Risk Profiles
No single toxicity profile applies to all hallucinogens. Risk varies enormously between subclasses.
Classical Psychedelics — Generally Low Acute Toxicity
LSD, psilocybin, DMT, and mescaline have extremely low acute physiological toxicity. No confirmed human fatalities from pharmacological overdose have been documented for these compounds. Primary risks are psychological: anxiety/panic, psychosis precipitation in predisposed individuals, and HPPD (rare).
Dissociatives — Moderate Risk with Serious Long-Term Concerns
Ketamine and related compounds have relatively low acute toxicity but carry serious long-term risks including ketamine cystitis (potentially permanent bladder damage), cognitive impairment with chronic use, and psychological dependence. Acute risks include cardiovascular stimulation, respiratory depression at anesthetic doses, and dissociation-related physical injury (falls, drowning).
Deliriants — High Risk
Anticholinergic deliriants from datura and belladonna carry genuine life-threatening toxicity risk even at moderate doses: cardiac arrhythmias, hyperthermia, rhabdomyolysis, and death. Unlike classical psychedelics, the LD50 is not far above doses that produce psychoactive effects. Diphenhydramine at recreational doses causes cardiac conduction abnormalities. These are among the most dangerous substances in this overview.
Universal Psychological Risks
Across all hallucinogen subclasses, the most consistent risk is psychological destabilization — acute panic, paranoia, and in severe cases lasting psychological sequelae. Risk is amplified by: personal or family history of psychosis, high doses, unfamiliar settings, concurrent stress, and polydrug use.
Overdose Information
Limited specific overdose data is available for Hallucinogens. In the absence of compound-specific information, general principles apply:
If someone exhibits signs of medical distress after using Hallucinogens — difficulty breathing, severe confusion, seizures, chest pain, extremely elevated temperature, or loss of consciousness — treat it as a medical emergency. Call emergency services and be forthcoming about what was consumed. Medical professionals follow confidentiality protocols and their priority is saving lives.
Prevention remains the best approach: use the minimum effective dose, avoid combining with other substances, and always have a sober person present who can recognize signs of distress and call for help.
Tolerance
| Full | Unknown |
| Half | Unknown |
| Zero | Unknown |
Legal Status
The legal status of Hallucinogens varies by jurisdiction and is subject to change. This information is provided for educational purposes and may not reflect the most current legislation.
General patterns: Many psychoactive substances are controlled under national and international drug control frameworks, including the United Nations Single Convention on Narcotic Drugs (1961), the Convention on Psychotropic Substances (1971), and country-specific legislation such as the US Controlled Substances Act, UK Misuse of Drugs Act, and EU Framework Decisions.
Research chemicals and analogues: Novel psychoactive substances may be captured by analogue laws (e.g., the US Federal Analogue Act) or blanket bans on substance classes (e.g., the UK Psychoactive Substances Act 2016), even if the specific compound is not individually scheduled.
Important note: Possessing, distributing, or manufacturing controlled substances carries serious legal consequences in most jurisdictions. Legal status is not a reliable indicator of a substance's safety profile — some highly dangerous substances are legal, while some with favorable safety profiles are strictly controlled.
Users are strongly encouraged to research the specific legal status of Hallucinogens in their jurisdiction before any involvement with this substance.
Experience Reports (1)
Tips (8)
Always start with a low dose of Hallucinogens and work your way up. Individual sensitivity varies, and you cannot undo a dose once taken.
Always reagent test psychedelics. Ehrlich for LSD and tryptamines, Marquis for phenethylamines and MDMA, Mandelin for ketamine. Many dangerous substances are sold as common psychedelics. NBOMe compounds in particular have caused deaths at doses sold as LSD. Testing takes 60 seconds and costs pennies.
Set (your mindset) and setting (your environment) account for more of the experience than the substance itself. If you are in a bad emotional state, in an unfamiliar or uncomfortable environment, or around people you do not fully trust, postpone. The substance will amplify whatever is already present.
The psychedelic experience does not end when the drug wears off. Integration — making sense of what you experienced and incorporating insights into daily life — is what determines whether the experience is transformative or just disorienting. Journaling, therapy, and integration circles are valuable tools.
Keep a usage log for Hallucinogens including dose, time, effects, and side effects. This helps you identify patterns and prevent problematic escalation.
Hallucinogens interact dangerously with several prescription medications. Lithium combined with psychedelics has caused seizures and death. MAOIs dramatically potentiate tryptamines and can cause serotonin syndrome. SSRIs typically reduce psychedelic effects but the interaction with some substances remains unpredictable.
Community Discussions (5)
References (2)
- Hallucinogens - TripSit Factsheet
TripSit factsheet for Hallucinogens
tripsit - Hallucinogens - Wikipedia
Wikipedia article on Hallucinogens
wikipedia